Long-term follow-up and late effects of childhood cancer: Viva

This is a branching oral built to probe the reasoning that holds the treatment exposure and the risk-based surveillance at the centre, and to expose the candidate who has memorised the headline without the corners. The questions escalate from the framing to the surveillance, the cardiac and the oncologic management, and the transition, with the deliberate probes into the pitfalls. [2]

Opening question: framing the problem

The examiner opens with the history and asks: how do you frame this problem in a single sentence, and what is your first priority? [1]

A strong answer names the childhood cancer survivor with the high-risk treatment exposures for the anthracycline cardiomyopathy and the radiation-associated breast cancer, and states that the exercise intolerance demands the urgent cardiac assessment. The first priority is the echocardiogram, because the cumulative anthracycline dose of three hundred milligrams per square metre exceeds the high-risk threshold of two hundred and fifty milligrams per square metre, and the cardiomyopathy can be silent for years before the heart failure declares. [5]

Model answer. This woman is a childhood cancer survivor at high risk of the anthracycline cardiomyopathy, because her cumulative anthracycline dose of three hundred milligrams per square metre exceeds the two hundred and fifty milligrams per square metre threshold, and her exercise intolerance demands the urgent echocardiogram and the cardio-oncology referral. My first priority is the cardiac assessment, and my second is the comprehensive risk-stratified surveillance built on her treatment summary. [5]

Probe one: the risk-stratified surveillance

The examiner presses: how do you build the surveillance plan for this survivor, and what drives each decision? [2]

A strong answer describes the treatment summary as the foundation, and the mapping of each exposure to the surveillance test against the Children's Oncology Group guidelines. The anthracycline dose drives the lifelong echocardiography, the chest radiation drives the annual mammography and the breast magnetic resonance imaging from eight years after the radiation or at age twenty five, whichever occurs later, and the chemotherapy and the radiation drive the endocrine panel and the thyroid surveillance. The surveillance is lifelong, and it is delivered in the late-effects clinic. [2]

Pitfall probe. Why does she need the breast magnetic resonance imaging in addition to the mammography, and why does it begin now? Because the chest radiation of thirty gray exceeds the twenty gray threshold, the breast tissue of the pubertal girl is exquisitely sensitive to the radiation, and the breast cancer risk approaches that of the BRCA carrier by the age of fifty. The surveillance begins at eight years after the radiation or at age twenty five, whichever occurs later, and she is twenty-two and fifteen years post-radiation, so she has entered the surveillance window. [9]

Probe two: the cardiac management

The examiner asks: the echocardiogram shows a reduced ejection fraction. How do you manage the anthracycline cardiomyopathy? [5]

A strong answer describes the early detection and the cardioprotection. The survivor with the falling ejection fraction is referred to the cardio-oncology service, and the angiotensin-converting-enzyme inhibitor or the angiotensin-receptor blocker is started to reduce the afterload and to slow the progression. The symptomatic heart failure is managed with the standard therapy, and the end-stage cardiomyopathy may require the heart transplantation. The avoidance of the additional cardiotoxicity, the blood-pressure control and the lifestyle form the preventive layer. [5]

Pitfall probe. Why is the anthracycline cardiomyopathy poorer in prognosis than the idiopathic? Because the anthracycline injures the terminally differentiated cardiomyocyte irreversibly through the free radical and the mitochondrial damage, so the cell loss is cumulative and the dysfunction progresses even after the exposure has ended, which is why the surveillance and the early intervention are so heavily weighted. [5]

Branch one: the endocrine and the fertility counselling

The examiner pivots: she asks whether she will be able to have children. How do you counsel her? [3]

A strong answer describes the gonadotoxicity of the alkylating agents and the radiation, the assessment of the hypothalamic-pituitary and the gonadal function, and the fertility preservation and the reproductive medicine referral. The alkylating agent dose, expressed as the cyclophosphamide-equivalent dose, predicts the gonadotoxicity, and the premature ovarian failure and the infertility are the presentations. The fertility preservation, the oocyte or the embryo cryopreservation, is offered before any further gonadotoxic therapy, and the reproductive medicine referral is made for the assessment and the counselling. [3]

Branch two: the acute presentation

The examiner pivots: imagine instead she presents to the emergency department with the shock and the hyponatraemia during an intercurrent illness. What is the diagnosis and the response? [3]

A strong answer names the adrenal crisis from the hypothalamic-pituitary failure, because the cranial radiation or the hypothalamic-pituitary damage may produce the adrenocorticotropin deficiency that declares as the crisis at the time of the stress. The response is the immediate intravenous hydrocortisone at the stress dose, the fluid and the glucose resuscitation, and the recognition that the cortisol deficiency is the cause. The survivor with the known adrenal insufficiency carries the emergency hydrocortisone and the sick-day plan, and the delay is the preventable death. [3]

Branch three: the second malignancy

The examiner pivots: she reports a palpable breast lump. How do you respond? [9]

A strong answer states that the new breast mass in a survivor with the chest radiation exposure is the radiation-associated breast cancer until proven otherwise, and the response is the urgent triple assessment with the clinical examination, the imaging and the biopsy. The breast magnetic resonance imaging and the mammography are the imaging, and the core biopsy is the histology. The default is to exclude the malignancy first, because the second malignancy is the leading cause of the premature death in the survivor, and the surveillance was built to intercept it at the earliest stage. [9]

Closing question: the transition

The examiner closes: she is twenty-two and ready to move to the adult service. How do you manage the transition? [11]

A strong answer describes the structured transition prepared in the adolescence, with the survivor taught the diagnosis, the exposures, the surveillance plan and the late-effect symptoms, and the written treatment summary and the care plan handed to the named adult provider. The transition is a clinical act, and the fellow who builds the transition plan demonstrates the care that extends the surveillance beyond the paediatric service and into the adult life. The loss to the follow-up is the greatest threat to the late-effect outcome, and the transition plan and the patient-held summary are the interventions that keep the survivor in the care. [11]